Division of Astellas Pharma Inc.
Latest From Agensys Inc.
Japanese firm unveils new capital investment program for novel biologics including antibodies and cell therapies as it ups full-year forecasts on strong US and global growth for Xtandi after a solid first half.
Astellas is looking to cut hundreds of positions in Japan as it faces a major upcoming patent expiry and refocuses under a new strategic plan.
Appointments: G1 Therapeutics, Breath Therapeutics, Fortress Biotech, Freeline Therapeutics, Enterome and Symic Bio
GSK's former CEO Sir Andrew Witty has joined the board of directors of the oncology company, G1 Therapeutics. This week's roundup also includes CEO appointments by Fortress Biotech, Freeline Therapeutics and BridgeSat, in addition to various other high-level appointments by Nabriva Therapeutics, Caribou Biosciences, Symic Bio and Breath Therapeutics.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.
- Large Molecule
- Therapeutic Areas
- UroGenesys Inc.
- North America
- Parent & Subsidiaries
- Astellas Pharma Inc.
- Senior Management
- Sef Kurstjens, MD, PhD, Pres. & CEO
- Contact Info
Phone: (424) 280-5000
1800 Stewart St.
Santa Monica, CA 90404